SCHEMBL8513627

SCHEMBL8513627

O=C(O)C[C@@H]1CC[C@H](c2ccccc2)N1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 7/20 0.49
S1PR1 P21453 7/20 0.49
S1PR5 Q9H228 7/20 0.49
S1PR3 Q99500 4/20 0.49
TP53 P04637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KCNH2 Q12809 4/20 0.43
SCN3A Q9NY46 1/20 0.43
USP30 Q70CQ3 1/20 0.41
DPP4 P27487 1/20 0.41
ITGB3 P05106 1/20 0.40
ITGB2 P05107 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGAV P06756 1/20 0.40
ITGA2B P08514 1/20 0.40
ITGA5 P08648 1/20 0.40
ITGB5 P18084 1/20 0.40
ITGAL P20701 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513587 1.00 S1PR4 (0.49) S1PR4S1PR1S1PR5S1PR3TP53
SCHEMBL5512850 0.81 TRPM5 (0.42) KCNH2SCN3ADPP4
SCHEMBL5512851 0.81 TRPM5 (0.42) KCNH2SCN3ADPP4
SCHEMBL12371304 0.81 MEN1 (0.41) KCNH2SCN3A
SCHEMBL4371456 0.78 HTR2C (0.41)
SCHEMBL5771665 0.76 POLB (0.47)
SCHEMBL23393883 0.76 MEN1 (0.50) KCNH2SCN3ADPP4
SCHEMBL13436114 0.76 MEN1 (0.50) KCNH2SCN3ADPP4
SCHEMBL1763221 0.76 MEN1 (0.50) KCNH2SCN3ADPP4
SCHEMBL1763291 0.76 MEN1 (0.50) KCNH2SCN3ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 US claimed
US-9512139-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2016-12-06 US claimed
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2015-02-19 US claimed
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-10-25 US claimed
EP-3087094-B1 BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS POLYPHOR AG (CH) 2022-06-01 EP disclosed
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 US disclosed
US-9284352-B2 Beta-hairpin peptidomimetics having CXCR4 antagonizing activity POLYPHOR AG (CH) 2016-03-15 US disclosed
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2015-02-19 US disclosed
US-8865656-B2 Beta-hairpin peptidomimetics having CXCR4 antagonizing activity POLYPHOR AG (CH) 2014-10-21 US disclosed
US-20120135942-A1 BETA-HAIRPIN PEPTIDOMIMETICS POLYPHOR AG (CH) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135942-A1 BETA-HAIRPIN PEPTIDOMIMETICS CXCR4, CXCL12, CXCR6 S1PR4 1442/4885S1PR1 1664/4885S1PR5 1812/4885
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds CTSE, CTSB, CTSS S1PR4 1087/4885S1PR1 922/4885S1PR5 1609/4885
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS KCNB1, KCNAB1, KCNMB1 S1PR4 868/4885S1PR1 507/4885S1PR5 632/4885
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS CTSE, CTSB, CTSS S1PR4 1087/4885S1PR1 922/4885S1PR5 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.